

Recommendations from York and Scarborough Medicines Commissioning Committee March 2019

	Drug name	Indication	Recommendation, rationale and place in therapy	RAG status	Potential full year cost impact
CCG commissioned Technology Appraisals					
1.	Nil				
NHSE commissioned Technology Appraisals – for noting					
2.	TA560 : Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)		NICE is unable to make a recommendation about the use in the NHS of bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer because no evidence submission was received from Roche.	BLACK	No cost impact to CCGs as NHS England commissioned and appraisal terminated by NICE.
3.	TA561 : Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia		Venetoclax with rituximab is recommended, within its marketing authorisation, as an option for treating chronic lymphocytic leukaemia in adults who have had at least 1 previous therapy. It is recommended only if the company provides it according to the commercial arrangement.	RED	No cost impact to CCGs as NHS England commissioned.
4.	TA562 : Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma		Encorafenib with binimetinib is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults. It is recommended only if the company provides encorafenib and binimetinib according to the commercial arrangements.	RED	No cost impact to CCGs as NHS England commissioned.
5.	TA563 : Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer		Abemaciclib with an aromatase inhibitor is recommended, within its marketing authorisation, as an option for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer as first endocrine-based therapy in adults. Abemaciclib is recommended only if the company provides it according to the commercial arrangement.	RED	No cost impact to CCGs as NHS England commissioned.
6.	TA564 : Dabrafenib with trametinib for treating advanced metastatic BRAF V600E		NICE is unable to make a recommendation about the use in the NHS of dabrafenib with trametinib for treating advanced metastatic	BLACK	No cost impact to CCGs as NHS England commissioned and appraisal terminated by

	mutation-positive non-small-cell lung cancer (terminated appraisal)	BRAF V600E mutation-positive non-small-cell lung cancer because no evidence submission was received from Novartis.		NICE.										
Formulary applications or amendments/pathways/guidelines														
7.	Opicapone 50mg capsules	<p>Adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.</p> <p>Application was approved for use second line subject to further clarification over the mechanism for defining criteria for success in the patient cohort. The development of a simple symptom improvement rating scale to be used for future formulary applications to be explored. In addition numbers of patients started on opicapone to be monitored to ensure use in line with application.</p>	AMBER SR	<p>15 patients per annum were likely to be suitable as identified by Neurology and Elderly Care physicians at YFT.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;">Product</th> <th style="width: 30%;">Monthly primary care cost</th> </tr> </thead> <tbody> <tr> <td>Opicapone 50mg daily</td> <td>£93.90 /30 days (Drug Tariff)</td> </tr> <tr> <td>Entacapone 200mg</td> <td>£10.32 to £34.40 /30days (assuming 3 to 10 tablets daily) (Drug Tariff)</td> </tr> <tr> <td>Generic brand of levodopa/carbidopa/entacapone All strengths- 3 tablets daily</td> <td>£62.38 /30 days (Drug tariff)</td> </tr> <tr> <td>Levodopa/carbidopa 100/25mg 3 tablets daily. Plus Opicapone 50mg once daily</td> <td>£17.40 /90 tabs Plus £93.90/30 caps = £111.30/ 30 days (Drug tariff)</td> </tr> </tbody> </table>	Product	Monthly primary care cost	Opicapone 50mg daily	£93.90 /30 days (Drug Tariff)	Entacapone 200mg	£10.32 to £34.40 /30days (assuming 3 to 10 tablets daily) (Drug Tariff)	Generic brand of levodopa/carbidopa/entacapone All strengths- 3 tablets daily	£62.38 /30 days (Drug tariff)	Levodopa/carbidopa 100/25mg 3 tablets daily. Plus Opicapone 50mg once daily	£17.40 /90 tabs Plus £93.90/30 caps = £111.30/ 30 days (Drug tariff)
Product	Monthly primary care cost													
Opicapone 50mg daily	£93.90 /30 days (Drug Tariff)													
Entacapone 200mg	£10.32 to £34.40 /30days (assuming 3 to 10 tablets daily) (Drug Tariff)													
Generic brand of levodopa/carbidopa/entacapone All strengths- 3 tablets daily	£62.38 /30 days (Drug tariff)													
Levodopa/carbidopa 100/25mg 3 tablets daily. Plus Opicapone 50mg once daily	£17.40 /90 tabs Plus £93.90/30 caps = £111.30/ 30 days (Drug tariff)													
8.	Algorithm for Management of Type 2 Diabetes	An updated local diabetes algorithm developed with the local diabetes team was approved. It has been updated to include an injectable pathway and guidance on management of diabetes in the over 75 age group. DPP4i agents were considered appropriate for use in elderly and frail patients.	n/a	No significant cost to CCGs expected as all the proposals are current practice.										

9.	GPs guidance on monitoring of patients post-bariatric surgery	A guideline for GPs on monitoring of patients post-bariatric surgery based on BOSS guidelines was approved.	n/a	No significant cost to CCGs expected as all the proposals are current practice.
10.	Guidance on Preservative Free Eye Drops	The guideline was approved. Concern raise over the potential numbers of patients who could be identified as suitable for preservative free formulations. However the guidance was accepted as explaining best practice with the opportunity to influence current prescribing practice.	n/a	Potential for cost saving as may ensure preservative free preparations as used more appropriately. (for example see cost comparison chart below)

